The medical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s exhibiting significant potential in clinical trials for treating obesity. Unlike some existing weight loss solutions, retatrutide appears to deliver a greater substantial decrease in body mass and benefit metabolic markers, particula